Please assess the completion status of the following clinical trial:

Trial Title: 3,3'-Dioxo-2,2'-Bisindolylidene-5,5'-Disulfonate Disodium 0.8% Solution as an Aid for Ureteral Patency

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects between ≥ 18 and ≤ 85 years old.~* Subjects who signed written, IRB approved, informed consent form.~* Subjects scheduled for urological or gynecological surgical procedures in which the patency of the ureter must be assessed by the surgeon during the procedure~Exclusion Criteria:~* Subjects with stage 4 or 5 Chronic Kidney Failure as evidenced by a GFR \<30 mL/min/1.73m2 (using the MDRD) or need for dialysis in the near future, or having only 1 kidney.~* Subjects with known severe hypersensitivity reactions to IC or other dyes including contrast agents.~* Known history of drug or alcohol abuse within 6 months prior to the time of screening visit.~* Subjects, as assessed by the Investigator, with conditions/concomitant diseases precluding their safe participation in this study (e.g. major systemic diseases).~* Unable to meet specific protocol requirements (e.g., scheduled visits) or subject is uncooperative or has a condition that could lead to non-compliance with the study procedures.~* Subject is the Investigator or any Sub-Investigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the protocol;~* Subjects with life expectancy \< 6 months;~* Requirement for concomitant treatment that could bias primary evaluation.~* Subjects who are pregnant or breast-feeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- HIGH DOSE (Type: EXPERIMENTAL): 48 subjects randomly treated with 5 mL of drug
- LOW DOSE (Type: EXPERIMENTAL): 48 subjects randomly treated with 2.5 mL of drug
- Saline (Type: PLACEBO_COMPARATOR): 96 subjects treated with 5 ml of saline than crossover to treatment arm

Based on this trial design, predict the completion outcome and termination type (if applicable).